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Abstract: Chimerism status evaluation is one of the most useful methods for the assessment of the hematopoietic stem 
cell transplantation outcome, since it gives information about engraftment and disease relapse, as well as providing 
indication for timely interventions such as donor lymphocyte infusions. The aim of this article is to give an overview of 
the different methods used for chimerism detection, with a especial emphasis on the quantitative PCR (qPCR) based 
techniques as the newest in line of techniques used for chimerism monitoring. This overview covers a description of the 
qPCR method as well as a discussion about the advantages this technique offers in comparison to other methods.  
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The assessment of the success of a medical treatment is 
always of great importance, and hematopoietic stem 
cell transplantation (HSCT), as a method of choice for 
treatment of numerous hematologic diseases and 
disorders, is no exception in this regard. The 
engraftment process and the detection of disease 
relapse are two key events which need to be monitored 
in post-HSCT patient follow-up procedures. Minimal 
residual disease (MRD) detection is an ideal procedure 
for the purpose of relapse detection because it reveals 
the presence of, for example, remaining leukemia 
cells.
1
 Unfortunately, specific markers have not been 
discovered for all diseases and alternative methods 
have been developed in order to bypass the time period 
until such markers become available for diagnostic 
purposes. One such method is the evaluation of 
chimerism status after HSCT, which can also give 




Chimerism, by medical definition, is a state in which 
two genetically different types of cells co-exist in one 
individual. It can happen naturally, for example after 
pregnancy, when maternal cells can be discovered in 
the child’s circulation after birth and vice versa. 
Conversely, chimerism occurs as a consequence of 




The aim of HSCT is to replace the patient’s 
hematopoietic system with donor’s cells, either because 
the patient’s cells do not function properly or have 
become malignant. If the main goal of the treatment is 
to restore the function of a cell line, such as for 
instance the T and B cell function in severe combined 
immunodeficiency (SCID) patients, then a complete 
replacement is not necessary, and a mixed chimerism, 
with both patient’s and donor’s cells detectable after 
transplantation, is sufficient for achieving adequate 
immune function. However, in cases when HSCT is 
performed in order to treat a malignant disease such as 
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acute myelogenous leukemia (AML), a complete 
conversion to a donor’s hematopoietic system is 
essential because the malignant potential of the 
remaining patient’ cells can be a cause for a disease 
relapse in the post-HSCT period. The accurate 
assessment of the chimeric status or, more precisely, 
determination whether the cells in the peripheral blood 
or bone marrow of the patient after transplantation are 




Initial protocols for HSCT almost always included 
myeloablative conditioning regimen in order to 
eradicate a patient’s hematopoietic system along with 
malignant cells and ensure engraftment by 
immunosuppression. The toxicity of these procedures, 
in terms of very serious side effects, meant that older 
patients or patients with comorbidities were excludes 
as possible candidates for HSCT. These patients, 
however, got the opportunity for treatment with HSCT 
with the advent of the so-called reduced intensity 
conditioning (RIC) regimens. This approach relies 
more on the graft-versus-tumor effect than the 
conditioning regimen for the reduction of the tumor 
burden prior to HSCT. Consequently, initial mixed 
chimerism is observed in the majority of patients 
undergoing HSCT, with RIC protocols and the need for 
continuous monitoring of the level of patient’s 




The aim of this article is to give a historic view of the 
methods used for chimerism analysis, describe the 
currently used gold-standard technique as well as 
inform about the latest developments and introduction 
of quantitative PCR technology in this field. 
 
 
CHIMERISM DETECTION METHODS – A 
HISTORICAL OVERVIEW 
Various different methods have been used throughout 
the last few decades in order to distinguish the origin of 
cells in a patient’s blood or bone marrow sample after 
HSCT, and therefore determine the chimerism status of 
the patient.
7, 8
 However, one aspect that all these 
techniques have in common is the overall procedure 
which consists of testing the patient and donor for 
genetic markers, identifying those markers for which 
the donor and patient differ, and subsequently testing 
those informative markers in the patient’s sample after 
HSCT. The comparison of sensitivity and applicability 
of used methods is shown in Table 1.
9
 
It is a well-known fact that the discovery of the 
polymerase chain reaction revolutionized molecular 
diagnostics in medicine. The identification of the so-
called repetitive DNA in the genome happened 
approximately at the same time, and the combination of 
these two discoveries led to the establishment of the 
method for chimerism detection which has been the 




Table 1. Sensitivity and informativity of methods used for 
chimerism detection after HSCT 
Method Sensitivity Informativity 
Erythrocyte phenotyping 0.04–3% Low 
Cytogenetics 5–10% Low 
FISH   0.7–5% High 
RFLP 5–10% High 
STR 0.4–5% Highest 
Real-time quantitative PCR 0.1–1% High 
 
 
Microsatellite or Short Tandem Repeats (STR) loci 
belong to the group of highly repetitive DNA, with a 
sequence comprised of two to six nucleotides repeated 
a variable number of times. These loci are highly 
polymorphic, with alleles differing in the number of 
repeats, and located throughout the entire genome. 
Although their first application was in the field of 
forensics, their potential for distinguishing the patient 
from the donor in the HSCT program was soon 
recognized. In addition to the fact that informative STR 
markers can easily be identified for virtually all 
patient/donor pairs, the method uses PCR amplification 
of these loci which is a fast, robust and reliable method, 
requires a small sample quantity and can be performed 
in the early post HSCT period. Further development of 
the method involved multiplexing of the PCR. The 
only disadvantage of the described technique is its 
relatively low sensitivity of 1-5% due to the fact that 
there is competition of the same primer for both minor 
and major cell population. This can be highly improved 
by performing the analysis on cell subsets; however, 
the need for cell sorting in such scenario adds to the 





QUANTITATIVE PCR IN CHIMERISM 
DETECTION 
A decade after the conventional PCR was described, a 
version of this technique was developed
12
 which 
enabled the measurement of the amount of amplified 
DNA in real time during amplification, therefore 
providing a quantitative analysis,. This method was 
called real-time PCR or quantitative PCR (qPCR). The 
most widely used approach, the probe-based qPCR, is 
presented in Figure 1. This approach utilizes 
fluorescently-labelled target-specific probes. These 
probes have a fluorescent reporter bound to one end, 
and a quencher of fluorescence bound to the other end. 
While the probe is bound to its specific target sequence 
on the DNA, the reporter and quencher are in close 
proximity, and the emission of fluorescence is 
prevented. However, during the elongation step of the 
PCR cycle, the 5' to 3' exonuclease activity of the Taq 
polymerase causes the hydrolyzation of the probe, the 
reporter   is  released,   and   emission   of  fluorescence  
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Figure 1. Probe- based qPCR method. 
 
 
occurs. The amount of the product targeted by the 
reporter probe is increased in subsequent cycles, which 
in turn causes a proportional increase of fluorescence.
13 
The measurement of fluorescence is performed for 
each amplification cycle and results in the 
amplification curve (Figure 2). The comparison of 
amplification curves of a patient’s samples, one taken 
before and the other after transplantation, provides 
relative quantification. The comparison requires setting 
a fixed fluorescence value across the graph, the so-
called threshold value. The number of cycles where the 
fluorescence reaches the threshold value is defined as 
the Cq value, and this value is inversely proportional to 
the amount of DNA present in the original sample. The 
system is calibrated using an internal control, usually 
by amplification of a housekeeping gene, therefore 
obtaining a normalized Cq value (Cq) ,which is in 
turn used to calculate the Cq value (number of 
additional cycles necessary to reach the threshold value 
of the post-transplant sample in comparison to the pre-
transplant sample). This is finally used to calculate the 
percentage of the recipient’s DNA in the post-
transplantation sample (Figure 3).
14
 
Although the number of qPCR-based diagnostic 
procedures increased rapidly since the very beginning, 
it took almost ten years for the first article to be 
published describing the new, qPCR-based method for 
chimerism analysis after HSCT. The sensitivity of the 
qPCR method of 0.1% represented a notable 
improvement in comparison to the PCR-STR method 
and therefore gained the interest of the scientific and 
medical community, especially in light of the concern 
that the 1-5% sensitivity limit of the PCR-STR method 




The disadvantages of the initial qPCR assays were that 
biallelic polymorphisms were analyzed which 
significantly decreased the applicability/ 
informativeness of the method in comparison to the 
PCR-STR technique; and the assays did not reach a 
reliable quantitative accuracy. The PCR-STR method 
therefore remained the first choice for chimerism 
detection throughout the next 15 years. 
Recent developments in qPCR-based chimerism 
assays, however, might change the current practice. 
Namely, in addition to recently published studies about 
the qPCR-based chimerism monitoring after HSCT,
15-18
 
several commercial kits have appeared on the market, 
utilizing the insertion/deletion polymorphisms, greatly 
increasing the applicability of the assay by enabling 
identification of at least one informative marker for  
>99% of patient/donor pairs. The marker is considered 
informative for the patient if the patient’s sample has a 
positive reaction while the donor’s sample is negative. 
The opposite rule applies for the markers informative 
for the donor. Possible combinations and their 
application are shown in Table 2. The number of 
informative loci is higher in cases when the donor is an 
unrelated individual. The sensitivity of the method, 
which is 20 to 100-fold higher than that of the PCR-
STR method, and reduced time necessary to perform 
the test because no post-PCR procedures are necessary 
have  been  incentive  enough  for many  laboratories to 
switch to qPCR-based methods for the monitoring of 




















Figure 2. qPCR fluorescence signal curve 
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Table 2. An example of a qPCR genotyping results 
KMR MARKER PATIENT DONOR INFORMATIVE FOR APPLICATION 
KMR013 positive negative recipient patient cells are minor population 
KMR028 negative positive donor donor cells are minor population 
KMR037 positive positive not informative - 




The high number of different methods and techniques 
used for the assessment of chimerism status 
demonstrates how the need for a more accurate, more 
sensitive and faster method in order to improve the 
post-transplantation patient care leads to scientific and 
technological developments. The rapid changes in 
methodology are another indicator of the importance of 
chimerism status analysis as it remains one of the 
major tools for the assessment of graft function, the 
prediction of disease relapse and making decisions 
about immunosuppression or medical interventions 
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